Stockscreener 앱 받기
0.2724
1.27%
-0.0035
전일 마감가:
$0.2759
열려 있는:
$0.2828
하루 거래량:
378.20K
Relative Volume:
0.37
시가총액:
$8.87M
수익:
-
순이익/손실:
$-98.79M
주가수익비율:
-0.0833
EPS:
-3.27
순현금흐름:
$-51.66M
1주 성능:
-8.19%
1개월 성능:
+3.61%
6개월 성능:
-92.17%
1년 성능:
-94.19%
1일 변동 폭
$0.245
$0.2828
1주일 범위
$0.245
$0.3259
52주 변동 폭
$0.2404
$5.09
Relmada Therapeutics Inc Stock (RLMD) Company Profile
명칭
Relmada Therapeutics Inc
전화
646 876 3459
주소
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
RLMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
19.95 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.16 | 304.74M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
MOBBW
Mobilicom Limited Warrants
|
0.265 | 278.60M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
3.25 | 142.54M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
10.50 | 141.55M | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-05 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-09-17 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-06-05 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-10-14 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-10-14 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-10-14 | 다운그레이드 | Truist | Buy → Hold |
| 2022-10-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-11-18 | 개시 | Mizuho | Buy |
| 2021-05-20 | 재개 | Goldman | Buy |
| 2020-10-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-07-14 | 개시 | Oppenheimer | Outperform |
| 2020-05-04 | 개시 | SunTrust | Buy |
| 2020-04-21 | 개시 | Goldman | Buy |
| 2020-01-27 | 개시 | Jefferies | Buy |
| 2020-01-10 | 개시 | SVB Leerink | Outperform |
| 2019-12-16 | 개시 | Guggenheim | Buy |
모두보기
Relmada Therapeutics Inc 주식(RLMD)의 최신 뉴스
Relmada outlines plans for NDV-01 Phase 2 results presentation and sepranolone development - MSN
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2024 Earnings Call Transcript - Insider Monkey
Relmada Therapeutics: Strategic Acquisitions and Pipeline Progress - TipRanks
Relmada Therapeutics pivots from psilocybin to cancer, neurological disorders - Green Market Report
Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights: Strategic Acquisitions and ... - Yahoo Finance
Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights - GuruFocus.com
Relmada Therapeutics Reports 2024 Financial Results and Strategic Progress - TipRanks
Earnings call transcript: Relmada Therapeutics Q4 2024 sees improved EPS By Investing.com - Investing.com South Africa
Earnings call transcript: Relmada Therapeutics Q4 2024 sees improved EPS - Investing.com India
RELMADA THERAPEUTICS Earnings Results: $RLMD Reports Quarterly Earnings - Nasdaq
Relmada Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update - The Manila Times
Relmada Cuts Losses by 25%: Key Pipeline Programs Hit Critical Phase in 2025 - Stock Titan
Relmada Therapeutics Inc -On March 24, Enters Exclusive License Agreement With Trigone PharmaSEC Filing - MarketScreener
Insights Ahead: Relmada Therapeutics's Quarterly Earnings - Benzinga
Mizuho maintains Relmada stock neutral with $1.00 target By Investing.com - Investing.com Canada
Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025 - Quantisnow
Mizuho maintains Relmada stock neutral with $1.00 target - Investing.com India
Mizuho Reiterates Neutral Rating on Relmada Therapeutics Inc (RLMD) - StreetInsider.com
Relmada secures exclusive license for potential bladder cancer therapy By Investing.com - Investing.com South Africa
Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd. - Quantisnow
Relmada secures exclusive license for potential bladder cancer therapy - Investing.com India
Relmada Therapeutics Announces Exclusive Licensing Agreement for NDV-01, a Novel Intravesical Therapy for Non-Muscle Invasive Bladder Cancer - Nasdaq
Relmada Therapeutics (RLMD) Licenses NDV-01 from Trigone Pharma - StreetInsider.com
Game-Changing Cancer Drug: Relmada's New Treatment Lasts 10 Days vs Hours - Stock Titan
RELMADA THERAPEUTICS Earnings Preview: Recent $RLMD Insider Trading, Hedge Fund Activity, and More - Nasdaq
Relmada Therapeutics Inc expected to post a loss of 70 cents a shareEarnings Preview - TradingView
Relmada Therapeutics (RLMD) Projected to Post Earnings on Tuesday - Defense World
Relmada seeking strategic options, stock climbs 5% - MSN
RELMADA THERAPEUTICS, INC. INVESTIGATION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Relmada Therapeutics, Inc. - ACCESS Newswire
Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight - GlobeNewswire Inc.
RLMD stock touches 52-week low at $0.28 amid market challenges - Investing.com Australia
RLMD stock touches 52-week low at $0.28 amid market challenges By Investing.com - Investing.com South Africa
A significant driver of top-line growth: Relmada Therapeutics Inc (RLMD) - SETE News
Relmada acquires new Tourette syndrome treatment asset - MSN
Relmada Therapeutics Inc [RLMD] Investment Guide: What You Need to Know - Knox Daily
RLMD stock’s current quarter earnings estimates: What analysts predict? - US Post News
Closing Strong: Relmada Therapeutics Inc (RLMD) Ends at 0.31, Down -9.62 from Last Close - The Dwinnex
Relmada Therapeutics Inc’s Shares Reel: -90.69% Quarterly Revenue Decline Amid 9.33M Market Cap - The InvestChronicle
A company insider recently bought 51,407 shares of Relmada Therapeutics Inc [RLMD]. Should You Buy? - Knox Daily
Mizuho maintains Neutral on Relmada stock, sees deal potential - MSN
The Tourette’s Deal That Came Too Late To Save Sweden’s Asarina - Insights
Relmada in-licenses Tourette syndrome drug from Asarina - The Pharma Letter
Take off with Relmada Therapeutics Inc (RLMD): Get ready for trading - SETE News
Relmada acquires Tourette’s therapy rights from Asarina - Yahoo Finance
Lipella Pharmaceuticals Inc [LIPO] Revenue clocked in at $0.48 million, up 52.46% YTD: What’s Next? - The DBT News
Relmada acquires new Tourette syndrome treatment asset By Investing.com - Investing.com Nigeria
Mizuho maintains Neutral on Relmada stock, sees deal potential By Investing.com - Investing.com Australia
Relmada Therapeutics Inc (RLMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Relmada Therapeutics Inc 주식 (RLMD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| TRAVERSA SERGIO | Chief Executive Officer |
Sep 09 '24 |
Buy |
2.71 |
55,579 |
150,619 |
299,603 |
| TRAVERSA SERGIO | Chief Executive Officer |
Sep 10 '24 |
Buy |
2.75 |
33,014 |
90,788 |
332,617 |
| CASAMENTO CHARLES J | Director |
Sep 09 '24 |
Buy |
2.56 |
13,000 |
33,280 |
13,000 |
| Shenouda Maged | Chief Financial Officer |
Sep 11 '24 |
Buy |
2.95 |
24,120 |
71,154 |
88,335 |
| Shenouda Maged | Chief Financial Officer |
Sep 10 '24 |
Buy |
2.73 |
21,118 |
57,652 |
64,215 |
| Shenouda Maged | Chief Financial Officer |
Sep 09 '24 |
Buy |
2.55 |
8,194 |
20,895 |
43,097 |
| Kelly Paul Edward | Director |
Sep 09 '24 |
Buy |
2.59 |
25,000 |
64,750 |
212,295 |
10.70%
자본화:
|
볼륨(24시간):